|Day Low/High||2.73 / 2.85|
|52 Wk Low/High||2.55 / 4.33|
The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.
Anti-tumor activity demonstrated in dose escalation trials for EC1456 and EC1169
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Endocyte Inc , where a total volume of 785 contracts has been traded thus far today, a contract volume which is representative of approximately 78,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 48.1% of ECYT's average daily trading volume over the past month, of 163,335 shares.
Supports Folate Receptor (FR) as a Valid Target in Non-Small Cell Lung Cancer (NSCLC)